Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: Multicentre, open-label, phase II safety study

European Journal of Cancer

Volumn 49, Issue 16, 2013, Pages 3412-3419

  Bruix, Jordi ^a   Tak, Won Young ^b   Gasbarrini, Antonio ^c   Santoro, Armando ^d   Colombo, Massimo ^e   Lim, Ho Yeong ^f   Mazzaferro, Vincenzo ^g   Wiest, Reiner ^h   Reig, María ^a   Wagner, Andrea ⁱ   Bolondi, Luigi ^j  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Kyungpook National University Hospital   (South Korea)

^c FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^f Sungkyunkwan University School of Medicine   (South Korea)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁱ BAYER PHARMA AG   (Germany)

^j S Orsola Malpighi Polyclinic ^*  (Italy)

more..

Author keywords

Hepatocellular carcinoma; Receptor kinase inhibition; Regorafenib; Safety Second line; Tolerability

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; CISPLATIN; CREATININE; DOXORUBICIN; GAMMA GLUTAMYLTRANSFERASE; GEMCITABINE; MITOXANTRONE; REGORAFENIB; SORAFENIB; THALIDOMIDE;

ABDOMINAL PAIN; ACIDOSIS; ADULT; ADVANCED CANCER; ADVANCED HEPATOCELLULAR CARCINOMA; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; BRAIN METASTASIS; CANCER MORTALITY; CENTRAL NERVOUS SYSTEM HEMORRHAGE; CLINICAL ARTICLE; CONSTIPATION; DEATH; DEPRESSION; DIARRHEA; DISEASE CONTROL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; FALLING; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEART ATRIUM FIBRILLATION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEMATOMA; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERTHYROIDISM; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INTERMEDIATE HEPATOCELLULAR CARCINOMA; INTRACRANIAL PRESSURE; LIVER CELL CARCINOMA; LIVER FUNCTION; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOOD CHANGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; ORAL MUCOSITIS; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; SKIN MANIFESTATION; SKULL BASE FRACTURE; SUBDURAL HEMATOMA; THROMBOCYTOPENIA; TREATMENT DURATION; VOICE CHANGE; VOMITING; WEIGHT REDUCTION;

HEPATOCELLULAR CARCINOMA; RECEPTOR KINASE INHIBITION; REGORAFENIB; SAFETY; SECOND LINE; TOLERABILITY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIA; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PYRIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885173677     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.05.028     Document Type: Article

References (23)

1. J.M. Llovet, and J. Bruix Novel advancements in the management of hepatocellular carcinoma in 2008 J Hepatol 48 Suppl. 2008 S20 S37
2. A. Forner, J.M. Llovet, and J. Bruix Hepatocellular carcinoma Lancet 379 2012 1245 1255
3. J.M. Llovet, S. Ricci, and V. Mazzaferro Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
4. A.L. Cheng, Y.K. Kang, and Z. Chen Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 2009 25 34
5. J. Bruix, and M. Sherman AASLD Practice Guideline. Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
6. C.R. de Lope, S. Tremosini, and A. Forner Management of HCC J Hepatol 56 Suppl. 2012 S75 S87
7. R.S. Finn Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin Cancer Res 16 2010 390 397
8. C. Cainap, S. Qin, and W.T. Huang Phase III trial of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) J Clin Oncol 30 Suppl. 2012 Abstract 249
9. Johnson P, Qin S, Park JW, et al. Brivanib (BRI) versus sorafenib (SOR) as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma (HCC): results from the phase 3 BRISK-FL study. 63rd annual meeting of the American Association for the Study of Liver Disease; 2012. Abstract LB-6.
10. Llovet JM, Decaens T, Raoul JL, et al. Brivanib versus placebo in patients with advanced hepatocellular carcinoma (HCC) who failed or were intolerant to sorafenib: results from the phase 3 BRISK-PS study. 47th annual meeting of the European Association for the Study of the Liver; 2012. Abstract 1398.
11. A. Cheng, Y. Kang, and D. Lin Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC) J Clin Oncol 29 Suppl. 2011 Abstract 4000
12. S. Faivre, E. Raymond, and E. Boucher Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study Lancet Oncol 10 2009 794 800
13. S.M. Wilhelm, J. Dumas, and L. Adnane Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity Int J Cancer 129 2011 245 255
14. K. Mross, A. Frost, and S. Steinbild A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic and stromal kinases, in patients with advanced solid tumors Clin Cancer Res 18 2012 2658 2667
15. T. Shimizu, A.W. Tolcher, and A. Patnaik Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors J Clin Oncol 28 Suppl. 2010 Abstract 3035
16. A. Grothey, E. Van Cutsem, and A. Sobrero Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
17. G.D. Demetri, P. Reichardt, and Y.K. Kang Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 295 302
18. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
19. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
20. R.S. Finn, G. Blumenschein, and A. Tolcher Continuous-dose regorafenib (REG) in hepatocellular carcinoma (HCC): phase I safety and pharmacokinetic (PK) study J Clin Oncol 30 Suppl. 2012 Abstract 300
21. T. Eisen, H. Joensuu, and P.D. Nathan Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial Lancet Oncol 13 2012 1055 1062
22. C.M. Booth, and E.A. Eisenhauer Progression-free survival: meaningful or simply measurable? J Clin Oncol 30 2012 1030 1033
23. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma Eur J Cancer 48 2012 599 641